At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AKTX Akari Therapeutics PLC
Market Closed 11-06 16:00:00 EST
7.37
-0.38
-4.90%
盘后7.37
+0.000.00%
16:10 EST
High8.38Low7.27Vol53.06K
Open7.77D1 Closing7.75Amplitude14.26%
Mkt Cap16.84MTradable Cap12.34MTotal Shares2.29M
T/O407.13KT/O Rate3.17%Tradable Shares1.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
MT Newswires Live  ·  11-06 00:05
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading
MT Newswires Live  ·  11-04
European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading
Akari Therapeutics Holds Special General Meeting
Reuters  ·  10-31
Akari Therapeutics Holds Special General Meeting
Akari Therapeutics Presents RNA-Splicing Payload Strategy at ADC Payload Summit
Reuters  ·  10-30
Akari Therapeutics Presents RNA-Splicing Payload Strategy at ADC Payload Summit
European Equities Traded in the US as American Depositary Receipts Steady in Wednesday Trading
MT Newswires Live  ·  10-28
European Equities Traded in the US as American Depositary Receipts Steady in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT Newswires Live  ·  10-27
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT Newswires Live  ·  10-26
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
MT Newswires Live  ·  10-19
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
Akari Therapeutics Grants Director Bazemore Restricted Stock Units in Lieu of Unpaid Cash Retainers
Reuters  ·  10-17
Akari Therapeutics Grants Director Bazemore Restricted Stock Units in Lieu of Unpaid Cash Retainers
Akari Therapeutics Targets Mid-2027 Start for AKTX-101 Phase 1 Trial
Reuters  ·  10-15
Akari Therapeutics Targets Mid-2027 Start for AKTX-101 Phase 1 Trial
Akari Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Vatnak Vat-Ho
Reuters  ·  10-15
Akari Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Vatnak Vat-Ho
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
MT Newswires Live  ·  10-14
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
Akari Therapeutics appoints Vatnak Vat-Ho as chief business officer
TIPRANKS  ·  10-13
Akari Therapeutics appoints Vatnak Vat-Ho as chief business officer
Press Release: Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Dow Jones  ·  10-13
Press Release: Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
European Equities Traded in the US as American Depositary Receipts Open Higher in Monday Trading
MT Newswires Live  ·  10-12
European Equities Traded in the US as American Depositary Receipts Open Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
MT Newswires Live  ·  10-09
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
Akari Therapeutics Raises CEO Abizer Gaslightwala Base Salary to $625,000
Reuters  ·  10-02
Akari Therapeutics Raises CEO Abizer Gaslightwala Base Salary to $625,000
Akari Therapeutics expands IP portfolio with PCT filing for ADC payload
TIPRANKS  ·  10-01
Akari Therapeutics expands IP portfolio with PCT filing for ADC payload
Akari Therapeutics Files PCT Patent Application for PH1 RNA-Splicing ADC Payload in Cancer
Reuters  ·  10-01
Akari Therapeutics Files PCT Patent Application for PH1 RNA-Splicing ADC Payload in Cancer
Akari Therapeutics Expands Intellectual Property Portfolio with Pct Filing for ADC Payload Related to Rna Splicing in Cancers
THOMSON REUTERS  ·  10-01
Akari Therapeutics Expands Intellectual Property Portfolio with Pct Filing for ADC Payload Related to Rna Splicing in Cancers

Introduction

Company Name.
Akari Therapeutics PLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Issue price:
--